Opinion

Video

Extended Follow Up of KEYNOTE-B61

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

Related Videos
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
2 KOLs are featured in this series
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Related Content